A Third Circuit Court of Appeals panel recently upheld a lower court’s decision to dismiss plaintiffs’ claims at summary judgment in a multi-district litigation involving Zoloft, an anti-depressant manufactured by Pfizer. The MDL involved 315 plaintiffs alleging that Zoloft causes cardiac birth defects when taken during early pregnancy. The decision, which upheld an earlier ruling by the U.S. District Court for the Eastern District of Pennsylvania, has both good and bad aspects for defendants facing pharmaceutical product liability claims.
The plaintiffs introduced several expert witnesses…
Continue reading...
Last month the Pennsylvania federal judge presiding over the multi-district litigation in which the plaintiffs allege that the prescription anti-depressant Zoloft, taken during pregnancy, causes birth defects, issued another in an series of Daubert rulings on the plaintiffs’ proposed experts as to general causation. Although the defendant conceded the qualifications of the three research scientists whose expert evidence was being tested, the reliability of their general causation opinions was hotly contested and received a full evidentiary hearing.
The Zoloft court’s rulings represent an important addition…
Continue reading...
Continue reading...
Litigation
Continue reading...
- Product Liability Cases to Watch in 2014 (subscription required)
- Master Complaint Approved for Granuflo Lawsuits Against Fresenius
- DePuy ASR Hip Settlement Requires Registration by Jan. 6
- SimplyThick Lawsuits Over Infant Injuries, Deaths Continue to Mount
- Motion Filed to Modify Zoloft Lawsuit Trial Pool in Federal MDL
- Product Liability Regulation to Watch in 2014 (subscription required)
- Antabloc Manufacturers Get FDA Warning Letter Over IBD Claims
Continue reading...
Litigation
Continue reading...
- High Court Denies Bid to Review Neurontin RICO Rulings (subscription required)
- Merck Settles Fosamax Jaw-Injury Claims for $28M (subscription required)
- Boehringer Fined $1M For Withholding Docs in MDL (subscription required)
- Expert Testimony Must be Backed By Science, Pa. Court Rules (subscription required)
- High Court Passes on Lupron Labeling Suit (subscription required)
- 1st Circ. Ends Takeda FCA Suit But Limits Scope of Ruling (subscription required)
- Medtronic Escapes Jury’s $18M Surgical Fire Verdict (subscription required)
- J&J Keeps Vaginal Mesh Suit Out of
Continue reading...
Litigation
Continue reading...
- Stryker Rejuvenate Lawsuits Filed by Nearly 1,000 Hip Patients Nationwide
- Novartis Can’t Apply NJ Punitives Cap in 3 Zometa Suits (subscription required)
- Pfizer Escapes FCA Suit Over Anti-Fungal Drug Promotions (subscription required)
- Gardasil Lawsuit Filed in France Over Side Effects of HPV Vaccine
- Judge Backs Jury Finding in J&J Body Powder Cancer Suit (subscription required)
- OxyElite Pro Class Action Filed Over False Advertising
- First Zoloft Trial in Federal MDL for Birth Defect Lawsuits to Begin Nov. 2014
- J&J Takes Innovative,
Continue reading...
Litigation
Continue reading...
- Remicade Lawsuit Filed Over Nerve Paralysis, Breathing Problems
- GNC Hit with Suit Linking Supplement to Hepatitis (subscription required)
- J&J to Pay $2.5B to Settle Hip Implant Litigation (subscription required)
- $25M Hydroxycut Settlement Denied in False Ad MDL (subscription required)
- J&J Unit Hit with Suit Over Rheumatoid Arthritis Drug (subscription required)
- AMS Pelvic Organ Prolapse Mesh Lawsuit Set for Trial in August 2014
- 8th Circ. Returns Boston Scientific Mesh Suits to Fed. Court (subscription required)
- 3rd Cir. Affirms Plavix
Continue reading...
In a controversial 2008 decision in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (Cal. Ct. App. 2008), a California Court of Appeals held defendant drug developer, Wyeth, Inc., liable for inadequate warnings in connection with the plaintiff’s use of a competitor’s generic version of the gastrointestinal reflux drug Reglan. The court in Conte held “the common law duty to use due care owed by a name-brand prescription drug manufacturer when providing product warnings extends not only to consumers of its own product,…
Continue reading...
Continue reading...
In a controversial 2008 decision in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89 (Cal. Ct. App. 2008), a California Court of Appeals held defendant drug developer, Wyeth, Inc., liable for inadequate warnings in connection with the plaintiff’s use of a competitor’s generic version of the gastrointestinal reflux drug Reglan. The court in Conte held “the common law duty to use due care owed by a name-brand prescription drug manufacturer when providing product warnings extends not only to consumers of its own product,…
Continue reading...
Continue reading...
Litigation
Continue reading...
- Pfizer Opposes Centralization of Lipitor Cases for Diabetic Women
- J&J Settles Risperdal Lawsuit Over Illegal Marketing for $2.2B
- High Court Won’t Hear Okla. Appeal Over Abortion-Drug Law (subscription required)
- Supreme Court Asked to Take Up Lupron Labeling Suit (subscription required)
- Granuflo Dialysate Lawsuits Conference to Discuss Pending Motions
- Intuitive Surgical Insurance for da Vinci Robot Lawsuits Challenged
- Pfizer Concealed Zoloft Ineffectiveness, Louisiana Lawsuit Claims
- Topomaz Birth Defect Lawsuit Results in $4M Jury Award
- Lipitor Diabetes Risk for Women was
Continue reading...